1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Perrigo Suffers As It Waves Goodbye To Rx

CEO Kessler Acknowledges ‘Disappointing’ Q3 As Prescription Business Divested

 
• By Dave Wallace

Perrigo CEO Murray Kessler has acknowledged “disappointing” third quarter results for the company during a transitional quarter that saw it finally divest its Rx prescription generics business ahead of its upcoming acquisition of consumer healthcare specialist HRA Pharma.

Hand sign arrivals departures
Perrigo says goodbye to the Rx business as it waits to absorb HRA • Source: Alamy

Perrigo CEO Murray Kessler has insisted that the company has a “bright future” despite acknowledging “disappointing third quarter results [that] reflect the continuing impacts of the challenging operating environment caused by the global COVID-19 pandemic.”

With Perrigo announcing on 6 July that it had completed the $1.55bn divestment of its prescription Rx business to Altaris Capital Partners – which has rebranded the unit as Padagis (Also see "Padagis Launches First-To-Market Zomig Nasal Spray Ahead Of Lannett" - Generics Bulletin, 18 November, 2021

More from Earnings

More from Business

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.